From the Journals

Early psychosis: No need for antipsychotics to recover?


 

“A pragmatic call”

Commenting on the British study in an accompanying editorial, Lena K. Palaniyappan, MD, University of Western Ontario, London, Canada, and Rajeev Krishnadas, MD, University of Glasgow, Scotland, write that any illness left untreated can become more challenging to treat, including psychosis.

“This should make early intervention in psychosis a pragmatic call with no prima facie argument against it,” they write. A reduction in DUP “underpins the rationale behind early detection and intervention in psychosis.”

The editorialists note that the relationship between DUP and successful treatment in early psychosis “strengthens the argument for more proactive early assessment and intervention to shorten treatment delay.

“As we have learnt over the past two decades, even punctual treatment when symptoms first arise continues to be too late when it comes to psychosis,” they write.

Francey also recognizes the value of early intervention in FEP. However, she noted that comprehensive psychosocial therapy might well prove effective enough to stave off antipsychotic therapy in a certain subset of patients.

“For some people, antipsychotics may never need to be introduced,” she said. “Some people recover from their first episode of psychosis and don’t go on to have any more, while others have an episodic illness,” she said.

If another episode develops and the symptoms come back, further psychosocial interventions could then be tried “or you might want to move on” to psychotic medication “because trying to get people better and functioning as well as they can is our primary aim,” Francey said.

The STAGES study was supported by the Australian National Health and Medical Research Council. The British study was funded by the UK Department of Health, the National Institute of Health Research, and the Medical Research Council. Francey and Krishnadas have reported no relevant financial relationships. Palaniyappan has received grants and personal fees from Janssen Canada and Otsuka Canada, grants from Sunovion, and personal fees from SPMM Course UK and the Canadian Psychiatric Association.

This article first appeared on Medscape.com.

Pages

Recommended Reading

‘Defending Jacob’ and defending psychiatry
MDedge Psychiatry
Aerobic exercise may up brain-training benefits in schizophrenia
MDedge Psychiatry
Schizoaffective disorder: A challenging diagnosis
MDedge Psychiatry
Psychiatrists report rare case of woman who thinks she’s a chicken 
MDedge Psychiatry
‘Staggering’ increase in COVID-linked depression, anxiety
MDedge Psychiatry
PANS may be more prevalent than thought
MDedge Psychiatry
ED visits for mental health, substance use doubled in 1 decade
MDedge Psychiatry
Chloroquine linked to serious psychiatric side effects
MDedge Psychiatry
Aggression is influenced by genetic, environmental factors
MDedge Psychiatry
Why are many of my patients doing better during the pandemic?
MDedge Psychiatry